IL283365A - Methods of treating follicular lymphoma - Google Patents

Methods of treating follicular lymphoma

Info

Publication number
IL283365A
IL283365A IL283365A IL28336521A IL283365A IL 283365 A IL283365 A IL 283365A IL 283365 A IL283365 A IL 283365A IL 28336521 A IL28336521 A IL 28336521A IL 283365 A IL283365 A IL 283365A
Authority
IL
Israel
Prior art keywords
methods
follicular lymphoma
treating follicular
treating
lymphoma
Prior art date
Application number
IL283365A
Other languages
Hebrew (he)
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of IL283365A publication Critical patent/IL283365A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
IL283365A 2018-11-30 2021-05-23 Methods of treating follicular lymphoma IL283365A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862773678P 2018-11-30 2018-11-30
PCT/US2019/063234 WO2020112761A1 (en) 2018-11-30 2019-11-26 Methods of treating follicular lymphoma

Publications (1)

Publication Number Publication Date
IL283365A true IL283365A (en) 2021-07-29

Family

ID=68966021

Family Applications (1)

Application Number Title Priority Date Filing Date
IL283365A IL283365A (en) 2018-11-30 2021-05-23 Methods of treating follicular lymphoma

Country Status (15)

Country Link
US (1) US20200171034A1 (en)
EP (1) EP3886992A1 (en)
JP (1) JP2022513666A (en)
KR (1) KR20210097160A (en)
CN (1) CN113164782A (en)
AU (1) AU2019388899A1 (en)
BR (1) BR112021009978A2 (en)
CA (1) CA3120960A1 (en)
EA (1) EA202191509A1 (en)
IL (1) IL283365A (en)
MA (1) MA54292A (en)
MX (1) MX2021006368A (en)
PH (1) PH12021551140A1 (en)
SG (1) SG11202105309YA (en)
WO (1) WO2020112761A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014168975A1 (en) * 2013-04-08 2014-10-16 Pharmacyclics, Inc. Ibrutinib combination therapy
CA2955744A1 (en) * 2014-08-01 2016-02-04 Pharmacyclics Llc Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor
CA2980393A1 (en) * 2015-03-18 2016-09-22 Memorial Sloan Kettering Cancer Center Methods for diagnosing and treating follicular lymphoma
MA41901A (en) * 2015-04-06 2021-04-14 Janssen Pharmaceutica Nv COMPOSITIONS CONTAINING IBRUTINIB
WO2017087947A2 (en) * 2015-11-19 2017-05-26 Pharmacyclics Llc Method of treatment of follicular lymphoma with a btk inhibitor

Also Published As

Publication number Publication date
EP3886992A1 (en) 2021-10-06
EA202191509A1 (en) 2021-10-26
WO2020112761A1 (en) 2020-06-04
CA3120960A1 (en) 2020-06-04
MX2021006368A (en) 2021-10-13
AU2019388899A1 (en) 2021-06-10
KR20210097160A (en) 2021-08-06
US20200171034A1 (en) 2020-06-04
JP2022513666A (en) 2022-02-09
MA54292A (en) 2021-10-06
BR112021009978A2 (en) 2021-08-17
SG11202105309YA (en) 2021-06-29
PH12021551140A1 (en) 2021-10-25
CN113164782A (en) 2021-07-23

Similar Documents

Publication Publication Date Title
IL266847B (en) Methods for treatment of cancer comprising tigit-binding agents
IL275663A (en) Methods of treating cancer
IL256056A (en) Ezh2 inhibitors for treating lymphoma
EP3634369C0 (en) Methods for treating chemically relaxed hair
IL286297A (en) Methods of treating minimal residual cancer
SG11202010793UA (en) Methods of treating cancer
IL272092A (en) Methods of treating behavior alterations
IL280721A (en) Treatment of relapsed follicular lymphoma
EP3271485A4 (en) Methods for diagnosing and treating follicular lymphoma
IL276890A (en) Regimens and methods of treating multiple sclerosis using ofatumumab
IL281792A (en) Treatment methods
SG11202005163PA (en) Methods of treating cancer
IL281600A (en) Methods of treating cancer
IL281839A (en) Treatment methods
IL277981A (en) Methods of treating cancer
ZA202006810B (en) Process for treating hair
SG11202105877YA (en) Method of treatment
IL283365A (en) Methods of treating follicular lymphoma
IL269123A (en) Methods of treating cancer
SG11201710199PA (en) Methods of treating multiple sclerosis
IL281343A (en) Methods for treating pancreatitis
ZA201906319B (en) Methods of treating depression
GB201820236D0 (en) Method of treatment
GB201820157D0 (en) Method of treatment
GB201801249D0 (en) Methods of treatment